How is the final price of platinib determined in health insurance negotiations?

Pralsetinib is a drug used to treat certain types of cancer. It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs). The original drug Platinib has been launched in China, but the medical insurance policy has not yet been approved, so there is no relevant price after medical insurance. Once the medical insurance regulations of Platinib are passed, its price will drop compared to the original price. The original drug currently on the market in China has a specification of 100mg*120 capsules and may cost around RMB 60,000 per box.

Platinib is mainly used to treat advanced or metastatic non-small cell lung cancer and thyroid cancer in adult and pediatric patients with RET fusion gene mutations. RET gene mutations are abnormal mutations in an oncogene that can promote the growth and spread of cancer cells. Platinib inhibits the growth of cancer cells by blocking the activity of this abnormally activated RET protein kinase.

Compared with traditional chemotherapy, platinib has a more precise targeting effect and therefore can provide more effective treatment effects. Clinical trial results show that Platinib has shown significant efficacy in the treatment of advanced NSCLC caused by RET fusion gene mutations. After patients receive platinib treatment, the tumor can be significantly reduced or stopped growing, and the patient's survival can be prolonged.

However, like all medications, platinib may cause some adverse effects. Common adverse reactions include fatigue, nausea, vomiting, diarrhea, loss of appetite and other digestive system problems, as well as high blood pressure, skin itching and other discomforts. Therefore, before using platinib, patients should inform their doctor of their detailed medical history and take the medication according to their doctor's instructions.